Objective-Cleaved high-molecular-weight kininogen (HKa), an activation product of the plasma kallikrein-kinin system, inhibits endothelial cell functions. We questioned whether HKa affects the function of endothelial progenitor cells (EPCs) and accelerates their senescence. Methods and Results-Treatment with HKa for 2 weeks markedly inhibited the formation of large colonies and proliferation of EPCs on collagen surfaces, whereas HKa did not affect collagen-mediated EPC adhesion and survival. Concomitantly, treated EPCs displayed flattened and giant cell morphological changes and formation of intracellular vacuoles. As determined by acidic ␤-galactosidase staining, HKa increased senescent EPCs by 2-and Ͼ3-fold after culture for 1 and 2 weeks, respectively. In addition, HKa suppressed the telomerase activity of EPCs. HKa concentration-dependently increased the generation of intracellular reactive oxygen species (ROS) and markedly upregulated p38 kinase phosphorylation and prosenescence molecule p16 INK4a expression. SB203580, a p38 inhibitor, attenuated the level of HKa-enhanced p16 
ndothelial progenitor cells (EPCs) are precursors to mature endothelial cells that display distinct characteristics. 1 These cells have the ability to be mobilized to the site of vascular injury or tissue ischemia, and they differentiate into mature endothelial cells, promoting reendothelialization and neovascularization. Thus, EPCs play an important role in endothelial cell and vessel maintenance. However, in patients with atherosclerosis and cardiovascular diseases, the number and function of EPCs are negatively correlated with the atherosclerotic risk factors, which may contribute to vascular dysfunction. 2 For example, the frequency of circulating EPCs is reduced 50% in patients with coronary artery disease, and their EPCs display an impaired migratory response. 3 Moreover, the clinical administration of EPCs to patients with cardiovascular diseases has had limited efficacy, whereas in animal models, EPCs successfully restore endothelial function and enhance angiogenesis after tissue ischemia. 4 Very likely, EPCs are targets of endogenous angiogenic inhibitors elaborated in the setting of atherosclerosis. 4 Therefore, understanding the factors that affect EPC function and number is important, because it could improve the specific therapies to ultimately correct EPC dysfunction and prevent progression of atherosclerosis.
The plasma kallikrein-kinin system (KKS) consists of the proteins factor XII, prekallikrein, and high-molecular-weight kininogen (HK). 5 This system displays multiple physiological and pathophysiological activities, such as blood pressure adjustment, modulation of thrombosis, and regulation of endothelial cell function and angiogenesis. Plasma HK is a major component of the KKS and is responsible for the association of this system with the cell surface. The membrane surface of endothelial cells is an important site for the assembly and activation of the KKS. 5 Activation of the KKS is triggered in vivo by tissue destruction or by thrombus development 6 and results in cleavage of HK by kallikrein into 2-chain HK (HKa). Unlike HK, HKa exposes its domain 5 to the surface on cleavage, thereby acquiring a function of antiadhesion. 7 This antiadhesive property enables HKa to inhibit endothelial cell proliferation and to induce endothelial apoptosis on extracellular proteins. 8, 9 On the basis of these investigations, we examined in this study whether HKa targets EPCs and regulates their function and number. Our data demonstrate that HKa inhibited clonogenic and proliferative capacities of EPCs and accelerated the onset of EPC senescence. HKa significantly increased intra-cellular reactive oxygen species (ROS) generation and p38 kinase phosphorylation. Moreover, HKa suppressed EPC telomerase activity and upregulated prosenescence molecule p16 INK4a expression. Our results provide an improved understanding of the contribution of the KKS cascade to EPC dysfunction in vitro and suggest candidate pathways for investigation of EPC dysfunction in subjects with atherosclerosis.
Materials and Methods

EPC Preparation
In this study, those EPCs referred to as endothelial colony-forming cells were isolated from peripheral blood, and their progenitor cell capacities were validated as previously described. 10, 11 To be defined as an EPC, endothelial colony-forming cells were examined for evidence of clonal proliferative potential, endothelial cell surface phenotype, and in vitro capillary lumen formation. In brief, after informed consent was obtained in accordance with the Declaration of Helsinki, human blood was collected from healthy volunteer donors. After 1:1 dilution with Hanks' buffered salt solution, blood was overlaid onto Ficoll-Paque and centrifuged at 740g for 30 minutes. Buffy coat mononuclear cells were collected and resuspended in complete endothelial growth culture medium-2 (EGM-2, Cambrex) with additives (Bullet Kit) provided by the manufacturer and 10% fetal bovine serum. The cells were cultured in a 6-well tissue culture plate precoated with type I collagen (BD Biosciences) at 37°C. Colonies appearing between 5 and 22 days of culture were identified as a well-circumscribed monolayer of cobblestone-appearing cells. EPCs at early passages (passage 1 to 3) were examined for the phenotypic and functional validation analysis.
Lentiviral Transduction of EPCs and Single-Cell-Based Colony Formation Assay
Lentivirus expressing enhanced green fluorescent protein (EGFP) was generated as previously described. 12 The initial mononuclear cells on collagen-coated plates were infected with the supernatant containing lentivirus-expressing EGFP diluted 1:1 with complete EGM-2. The culture medium was replaced every 2 days. After 3 weeks, EGFPpositive EPCs (EGFP-EPCs) were observed under fluorescence microscope and sorted by fluorescence cytometry. A single EGFP-EPC was placed in 1 well of a 96-well tissue culture plate precoated with type 1 collagen containing EGM-2 medium. After 24 hours, individual wells were examined under a fluorescence microscope, and the wells that contained only 1 cell were scored in the assay. The cell culture medium was changed every 2 days. On day 14, each well was examined under a fluorescence microscope, and wells in which 2 or more endothelial cells were counted were scored positive for proliferation.
Data Analysis
Unless stated otherwise, the results shown are from a single experiment representative of at least 3 separate experiments. The data were calculated as averageϮSEM from experiments done at least 3 times and statistically analyzed by the Student t test (2 groups only) or 1-way ANOVA and the Student-Newman-Keuls test (multiple groups). 13 Differences with probability values below 0.05 were considered significant.
The Supplemental Data (available online at http://atvb.ahajournals.org) provide a complete description of materials and methods used for reagents, cell proliferation assay, measurement of mRNA expression by reverse transcription-polymerase chain reaction, immunoblot analysis and adhesion assay, senescence-associated ␤-galactosidase activity assay, terminal deoxynucleotidyl transferase dUTP nick-end labeling-based apoptosis detection assay, intracellular ROS production, and telomerase activity assay.
Results
HKa Suppresses Clonogenic Capacity of EPCs
As described in our previous studies, 10 -12 EPCs have been isolated and expanded ex vivo from adult peripheral blood mononuclear cells. We analyzed the clonogenic capacity of EPCs by using a single-cell assay previously described. 12 Within the first week after isolation, mononuclear cells were cultivated in the EGM-2 containing lentivirus-expressing EGFP, followed by culture in EGM-2. A single colony of EPCs uniformly expressing EGFP appeared in most wells ( Figure 1A ), and the colonies were collected for subsequent studies. To test whether HKa affects the clonal expansion potential of EPCs, a single-cell suspension of EGFP-EPCs was seeded into 96-well culture plate precoated with collagen. Because it has been observed that more than 30% of plasma HK is cleaved in patients with sepsis and autoimmune diseases, 14, 15 in this study we chose concentrations of HKa between 30 and 100 nmol/L, 5% to 15% of plasma concentration (660 nmol/L). The culture medium EGM-2 was replaced every 2 days. After culture for 14 days, EGFP-EPCs formed large colonies ( Figure 1B) , and Ϸ85% of colonies contained more than 200 cells (large colonies; Figure 1C ). However, in the presence of 50 nmol/L HKa, the percentage of large colonies was markedly reduced to Ͻ6% (PϽ0.001, Figure  1B and 1C), indicating that HKa strongly inhibits clonogenic capacity of EPCs.
HKa Inhibits EPC Proliferation Without Induction of Apoptosis
HKa inhibition of EPC colony formation suggested that HKa suppresses proliferation of EPCs. We therefore examined the effect of HKa on proliferative capacity of EPCs using a 5-bromo-2Ј-deoxyuridine incorporation assay. Figure 2A indicates that treatment of EPCs with HKa for 72 hours significantly inhibited vascular endothelial growth factorstimulated 5-bromo-2Ј-deoxyuridine incorporation into EPCs, and the inhibition was concentration-dependent, whereas the significant inhibitory effect of HKa was detectable only at 100 nmol/L after treatment for 48 hours. In contrast to its significant effects on proliferation, HKa at the same concentrations did not inhibit EPC adhesion to collagen ( Figure 2B ), suggesting that HKa inhibition of EPC proliferation does not result from an antiadhesion activity. Because HKa induces apoptosis of differentiated endothelial cells on vitronectin-coated surfaces, 9 we examined the effect of HKa on EPC apoptosis. Figure 3 indicates that HKa did not induce EPC apoptosis on collagen surfaces, although its effect on induction of EPCs apoptosis on vitronectin-coated plates was significant. Therefore, HKa inhibition of EPC colony formation and proliferation is not subject to antiadhesive activity and induction of apoptosis.
HKa Accelerates the Onset of EPC Senescence and Suppresses Telomerase Activity
Reduction of EPCs in number and activity has previously been associated with EPC senescence. 16 The common fea- tures of senescent endothelial cells include the enhanced presence of acidic ␤-galactosidase activity, an increase in lysosomal mass, and formation of autophagic vacuoles. 17 To determine whether HKa induces EPC senescence, we measured the activity of acidic ␤-galactosidase, referred as senescenceassociated-␤-galactosidase (SA-␤-gal). Although a small portion of EPCs were positive for SA-␤-gal staining after culture for 14 days ( Figure 4A and 4B) , in the presence of 50 nmol/L HKa, the majority of EPCs became positive for SA-␤-gal staining ( Figure  4) . Moreover, EPCs treated with 50 nmol/L HKa displayed a unique flattened and enlarged morphology and formed intracellular vacuoles ( Figure 4A ). Figure 4B demonstrates that HKa treatment significantly resulted in an increase in SA-␤-galpositive cells, 17.2Ϯ2.6% vs 52.3Ϯ3.7% on day 7 and 22.3Ϯ2.7% vs 85.5Ϯ7.9% on day 14. Acceleration of the onset of EPC senescence is known to be critically influenced by the level of telomerase activity, which elongates telomeres, thereby counteracting telomere length reduction induced by each cell division. 18 Therefore, we tested whether HKa treatment was capable of regulating telomerase activity in EPCs. Figure 4C demonstrates that treatment of EPCs with 50 nmol/L HKa for 14 days markedly diminished telomerase activity by Ͼ60% (PϽ0.005), serving as additional evidence for HKa acceleration of EPC senescence.
HKa Increases Intracellular ROS Production, Contributing to EPC Senescence
It has been well documented that cell senescence is tightly associated with intracellular ROS production. 18 We tested whether HKa exposure increases intracellular ROS in EPCs using the 2=-7=-dichlorodihydrofluorescein diacetate (H 2 DCF-DA) labeling assay. As shown in Figure 5A , in a concentration-dependent manner, HKa significantly increased H 2 DCF-DA oxidation level in exposed EPCs. Therefore, we hypothesized that HKa accelerates EPC senescence via ROS production, and performed an inhibition assay using the ROS scavengers Mn(III)tetrakis(4-benzoic acid)porphyrin chloride (MnTBAP) and N-acetylcysteine (NAC). MnT-BAP is a cell-permeable superoxide dismutase mimetic and peroxynitrite scavenger. NAC is an efficient free radical scavenger and contributes to production of other antioxidant species. Treatment with either 100 mol/L NAC or 10 mol/L MnTBAP significantly attenuated the increase in ROS production in EPCs treated with 100 nmol/L HKa for 12 hours (Supplemental Figure I) . Moreover, 100 mol/L NAC or 10 mol/L MnTBAP significantly reduced both the percentage of senescent cells and ROS production in EPCs treated with 50 nmol/L HKa for 14 days ( Figure 5B and 5C ). These observations suggest that HKa generation of ROS is involved in the acceleration of EPC senescence.
HKa Upregulates p38 Kinase Phosphorylation and p16 INK4a Expression
To investigate the mechanism for HKa acceleration of EPC senescence, we measured the levels of p38 kinase activation and prosenescence molecule p16 INK4a expression, which are downstream of ROS generation in the process of cellular senescence. 19 Immunoblotting analysis indicated that during the 7-day experimental period, phosphorylation of p38 kinase was increased by HKa at 30 and 100 nmol/L ( Figure 6A ). Concomitantly, HKa upregulated p16 INK4a expression at the protein level ( Figure 6A ). Figure 6B shows an increase in p16
INK4a mRNA expression in HKa-treated EPCs. To determine the connection between p38 kinase activation and p16
INK4a expression, EPCs were treated with SB203580, a specific p38 kinase inhibitor. Figure 6C demonstrates that 10 mol/L SB203580 markedly suppressed HKa-induced p16 INK4a expression, suggesting that HKa upregulates p16
INK4a expression via its activation of p38 kinase. Moreover, 10 mol/L SB203580 significantly attenuated HKamediated EPC senescence ( Figure 6D ). 
Discussion
Our current study reveals for the first time that HKa accelerates the onset of EPC senescence and induces typical morphological changes of EPC senescence. Consistently, HKa inhibited telomerase activity and the clonogenic and proliferative capacities of EPCs. HKa treatment increased intracellular ROS generation, and the quenching of ROS by NAC and MnTBAP prevented HKa-induced EPC senes- cence. HKa treatment enhanced p38 kinase phosphorylation and upregulated p16
INK4a expression in the exposed EPCs. Inhibition of p38 kinase by SB203580 attenuated HKaincreased p16
INK4a expression and EPC senescence. Thus, this study demonstrates novel activities of HKa in regulating several key elements of EPC biology.
Aging is associated with an increased risk for atherosclerosis, and insufficient repair of damaged vascular walls by a diminished number or dysfunction in EPC is one of many possible causes. 3 A reduction in EPC number and activity has been associated with EPC senescence. 14 Because senescence limits the ability of EPCs to sustain ischemic tissue repair, a full characterization of the pathophysiological factors leading to EPC senescence, as well as the related underlying mechanisms, is clearly important. Our current study demonstrating HKa acceleration of EPC senescence not only expands our understanding of the KKS activation in the regulation of vascular biology but also reveals a potential novel endogenous inducer of EPC senescence.
The in vivo activation of the KKS and cleavage of HKa has been widely detected in numerous pathophysiological conditions, such as thrombosis, 6 arthritis, 20 inflammatory bowel disease, 21 vasculitis, 22 sepsis, 23 systemic amyloidosis, 24 and preeclampsia. 25 However, our understanding of how the KKS activation products initiate and regulate downstream effects remains elusive. It has been well documented that HKa inhibits the function of differentiated endothelial cells, such as human umbilical vein endothelial cells in vitro, as well as perturbing in vivo angiogenesis. 26, 27 In this study, our results have provided new evidence that HKa targets EPCs and accelerates the onset of their senescence. The plasma concentration of HK is 660 nmol/L. In patients with sepsis and autoimmune diseases, more than 30% of plasma HK was cleaved. 14, 15 Because the minimal concentration of HKa that significantly induced EPC senescence was 30 nmol/L (data not shown), the circulating levels of HKa in the pathological settings could affect EPC function. This HKa-mediated effect was associated with profoundly impaired EPC clonal expansion potential and resulted in a low overall proliferative capacity of the EPC progeny. Because HK is localized at sites of vascular injury, such as atherosclerotic lesions, 28 it might become cleaved over the abundant negative-charged surfaces to release HKa. The observation that HKa potently inhibited the clonogenic capacity of EPCs suggests that HKa is possibly involved in the vascular dysfunction by blocking EPC aggregation and expansion. Because HKa inhibition of EPC function is not dependent on its antiadhesion activity, HKa in plasma may attack circulating EPCs. Although this study provides the first evidence for prosenescent activity of HKa, whether the blockade of HK cleavage prevents EPC senescence remains to be determined using an in vivo model. EPC senescence can be triggered by a variety of factors, such as proinflammatory cytokines, DNA damage, hyperoxia, and hyperglycemia. 18 All these factors increase oxidative stress, by which they induce EPC senescence and suppress telomerase activity. 16 The mechanism by which HKa accelerates the onset of senescence of EPCs seems to be tightly associated with ROS production. NAC and MnTBAP, which quench ROS, significantly attenuated HKa-induced EPC senescence ( Figure 5 ). A previous study has shown that HKa inhibits Akt phosphorylation and endothelial nitric oxide synthase phosphorylation, 29 which may inhibit the production of nitric oxide (NO). Although NO prevents endothelial cell senescence, 30 the NO donor S-nitrosopenicillamine did not prevent HKa-accelerated onset of EPCs senescence (data not shown). Thus, HKa regulation of EPC senescence appears independent of the NO pathway. Accumulation of ROS in most cell types is associated with high expression of p16 INK4a , which leads to the arrest of the cell cycle at the G 1 phase and accelerates senescence of cells. 31 The expression of p16
INK4a increases with age and contributes to age-dependent stem and progenitor cell senescence. 32 It can be deduced that accumulative ROS exposure, caused by various atherosclerotic risk factors, may also increase the expression of p16
INK4a in EPCs, contributing to EPC senescence. We found that HKa increased expression of p16
INK4a at the mRNA and protein level (Figure 6 ), demonstrating that HKa accelerates EPC senescence by the regulation of p16
INK4a expression. We previously have found that p38 kinase is responsible for mediating the effect of HKa in other cells. 33 Our observations in this study indicate that HKa enhances phosphorylation of p38 kinase, and the inhibition of p38 kinase prevented both HKa-induced p16
INK4a expression and EPC senescence. Therefore, HKa-induced ROS seems to act through p38 kinase to upregulate prosenescence molecule p16
INK4a expression, which may further regulate telomerase activity and result in EPC senescence.
In conclusion, the present study demonstrates that HKa accelerates the onset of EPC senescence by the activation of the ROS/p38 kinase/p16
INK4A signaling cascade. This activity of HKa reveals a novel link between KKS activation and vascular dysfunction, and it expands our understanding of the additional pathophysiological activities of this system. Although it remains to be determined whether and how HKa inhibition of EPCs is involved in the disordered vascular remodeling that occurs in vivo, our novel recognition that components of plasma KKS modulate EPC function allows for focused determination of the pathophysiologic activities of plasma KKS in atherosclerosis in future studies.
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